oxazoles has been researched along with oritavancin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strain, J | 1 |
| Hussar, DA | 1 |
| Burnham, CA; Crotty, MP; Krekel, T; Ritchie, DJ | 1 |
| Bassetti, M; Concia, E; Cristini, F; De Rosa, FG; Esposito, S; Menichetti, F; Petrosillo, N; Russo, A; Tumbarello, M; Venditti, M; Viale, P; Viscoli, C | 1 |
| Li, R; Nailor, MD | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
2 review(s) available for oxazoles and oritavancin
| Article | Year |
|---|---|
New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Topics: Anti-Infective Agents; Drug Approval; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Teicoplanin; United States; Vancomycin-Resistant Enterococci | 2016 |
Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Topics: Ambulatory Care; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Organophosphates; Oxazoles; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Teicoplanin; United States; United States Food and Drug Administration | 2016 |
4 other study(ies) available for oxazoles and oritavancin
| Article | Year |
|---|---|
Three new agents added to the arsenal to fight MRSA.
Topics: Anti-Bacterial Agents; Drug Approval; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Streptococcal Infections; Teicoplanin; United States; United States Food and Drug Administration | 2014 |
New drugs 2015, part 2.
Topics: Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Benzofurans; Cyclopropanes; Diphosphates; Drug Approval; Drug Therapy; Glucagon-Like Peptide 1; Glucosides; Glycopeptides; Humans; Lactones; Lipoglycopeptides; Organophosphates; Oxazoles; Pyridines; Sulfates; Teicoplanin; United States; United States Food and Drug Administration | 2015 |
New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
Topics: Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Glycopeptides; Humans; Lipoglycopeptides; Organophosphates; Oxazoles; Practice Guidelines as Topic; Skin Diseases, Bacterial; Teicoplanin; Treatment Outcome | 2016 |
Antibiotics.
Topics: Acute Disease; Anti-Bacterial Agents; Glycopeptides; Humans; Lipoglycopeptides; Organophosphates; Oxazoles; Skin Diseases, Bacterial; Teicoplanin | 2017 |